U.S. Patent and Trademark Office

The U.S. Patent Office ruled Monday that patents for some CRISPR technologies do not belong to the university and other partner institutions.

The UC system was awarded a patent Tuesday, marking the university's 16th patent for the CRISPR-Cas9 patent portfolio — the highest number in the country.

The UC system and partners University of Vienna and Emmanuelle Charpentier were awarded a 12th patent for the CRISPR-Cas9 gene-editing technology. 

The UC’s family of eight patents covers CRISPR methods for editing genes in any environment, whether the cells are in a plant, an animal or a human. This newest patent focuses specifically on the use of CRISPR gene editing within cells.

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office announced an interference between multiple UC and multiple Broad Institute patents, a signal that the USPTO will resolve the seven-year ownership debate regarding CRISPR-Cas9 genome editing in eukaryotic cells.

UC Berkeley announced Tuesday that the U.S. Patent and Trademark Office has granted a patent to CRISPR, a gene-editing technology.

Claiming 524 utility patents for 2017, the ten UC campuses have continuously held first place by a margin more than 100 utility patents since the NAI’s first ranking in 2013.

The U.S. Patent and Trademark Office issued Caribou Biosciences, a startup co-founded by UC Berkeley researcher Jennifer Doudna, intellectual property rights for developments in CRISPR gene-editing technology Tuesday.

The U.S. Patent and Trademark Office agreed Monday to decide whether a UC Berkeley research team will be awarded the rights to the groundbreaking CRISPR-Cas9 technology, which could be worth billions of dollars and serve as the foundation for the burgeoning field of gene editing.